Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIP: Psilocybin-Assisted Psychotherapy in Advanced Cancer
NCT06200155Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in major depressive disorder (MDD), anxiety disorder, sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2024; status: recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on NCT06200155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06200155.